ARCHIVES

ODAC votes 9-6 in favor of Clolar for pediatric acute lymphoblastic leukemia, but votes against Marqibo for non-Hodgkin’s lymphoma.

This article is from The Cancer Letter archive.

Vol. 30 No. 46 | December 10, 2004

Download PDF Visit The Full Archive

Related Articles

Avastin-Zybrestat Combination Increases Progression-Free Survival in Phase II Trial

March 28, 2014

FDA Committee Okays Carboplatin For Second Line Ovarian Cancer

January 6, 1989

Former NIH Director Varmus calls for more oversight of conflicts, expresses surprise at growth of Title 42 program.

May 21, 2004

Oncology Nursing Exam to Be Offered In 1990; 79% Passed Last Year

November 24, 1989

In Brief: Angel Bradley, NCAB Member, Dies; Three State Colorectal Cancer Screening Effort Big Success

July 5, 1985

ASCO Highlights Seven of 4,000 Abstracts Submitted for Annual Meeting, June 3-7

May 27, 2011